GSGTF (Gensight Biologics) Other Financing: $-0.24 Mil (TTM As of Dec. 2025)


What is Gensight Biologics Other Financing?

Gensight Biologics GSGTF Other Financing is $-0.24 Mil as of Dec. 2025. The stock has 8 warning signs investors should review.

Gensight Biologics's Other Financing for the six months ended in Dec. 2025 was $0.01 Mil.

Gensight Biologics's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.24 Mil.

Gensight Biologics Other Financing Historical Data

* Premium members only.

The historical data trend for Gensight Biologics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gensight Biologics Other Financing Chart

Gensight Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 30.80 -1.98 -0.40 -0.29 -0.25

Gensight Biologics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.21 -0.06 -0.23 -0.25 0.01

Gensight Biologics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $-0.24 Mil mean?
Gensight Biologics (GSGTF) has a Other Financing of $-0.24 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Gensight Biologics and its competitors.
Is Gensight Biologics' Other Financing too high?
Gensight Biologics' current Other Financing is $-0.24 Mil.
How does Gensight Biologics' Other Financing compare to VRTX and REGN?
Gensight Biologics' Other Financing of $-0.24 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Gensight Biologics and its competitors. Gensight Biologics's current Other Financing is $-0.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gensight Biologics stock overvalued right now?
Based on GuruFocus' analysis, Gensight Biologics (GSGTF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.04, compared to a current price of $0.09 — trading 125% above its estimated fair value. The current Other Financing is $-0.24 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Gensight Biologics (GSGTF), the current Other Financing is $-0.24 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gensight Biologics Business Description

Address 74, rue du Faubourg Saint-Antoine, Paris, FRA, 75012
Gensight Biologics SA is a clinical-stage biopharma company focused on developing and commercializing gene therapies for retinal neurodegenerative diseases and central nervous system disorders. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.